Should I buy or sell Tarsus Pharmaceuticals stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Tarsus Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" TARS shares. View TARS analyst ratings or view top-rated stocks .

What is Tarsus Pharmaceuticals' stock price target for 2024?

4 brokerages have issued 1 year target prices for Tarsus Pharmaceuticals' stock. Their TARS share price targets range from $19.00 to $54.00. On average, they expect the company's share price to reach $43.20 in the next twelve months. This suggests a possible upside of 161.3% from the stock's current price. View analysts price targets for TARS or view top-rated stocks among Wall Street analysts .

How have TARS shares performed in 2023?

Tarsus Pharmaceuticals' stock was trading at $14.66 at the beginning of the year. Since then, TARS shares have increased by 12.8% and is now trading at $16.53. View the best growth stocks for 2023 here .

When is Tarsus Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 11th 2024. View our TARS earnings forecast .

How were Tarsus Pharmaceuticals' earnings last quarter?

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) posted its quarterly earnings results on Tuesday, November, 9th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by $0.34. The firm earned $1.24 million during the quarter, compared to analysts' expectations of $1 million.

What ETF holds Tarsus Pharmaceuticals' stock ?

Invesco Raymond James SB-1 Equity ETF holds 39,637 shares of TARS stock, representing 0.71% of its portfolio.

When did Tarsus Pharmaceuticals IPO?

(TARS) raised $80 million in an initial public offering (IPO) on Friday, October 16th 2020. The company issued 5,000,000 shares at $15.00-$17.00 per share. BofA Securities, Jefferies and Raymond James served as the underwriters for the IPO and LifeSci Capital and Ladenburg Thalmann were co-managers.

Who are Tarsus Pharmaceuticals' major shareholders?

Tarsus Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include RTW Investments LP (8.70%), Cowen AND Company LLC (5.51%), Deerfield Management Company L.P. Series C (2.28%), Artisan Partners Limited Partnership (1.22%), Allspring Global Investments Holdings LLC (0.75%) and Schonfeld Strategic Advisors LLC (0.74%). Insiders that own company stock include Aziz Mottiwala , Bobak R Azamian, Bobak R Azamian , Bryan Wahl, Dianne C Whitfield, Elizabeth Yeu Lin, Jose M Trevejo, Leonard M Greenstein, Mark J Holdbrook, Michael Ackermann , Rtw Investments, Lp, Seshadri Neervannan and Vivo Capital Ix, Llc. View institutional ownership trends .

How do I buy shares of Tarsus Pharmaceuticals?

Shares of TARS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Positive News SentimentPositive News

Tarsus Pharmaceuticals Stock Price, News & Analysis (NASDAQ:TARS)

$16.53

+0.06 (+0.36%)

(As of 11/30/2023 ET)

Compare

Today's Range: $16.03
▼
$16.77
50-Day Range: $12.98
▼
$18.86
52-Week Range: $11.33
▼
$25.25

Volume: 471,868 shs
Average Volume: 309,315 shs
Market Capitalization: $547.14 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $43.20

Tarsus Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.75 Rating Score
Upside/Downside: 161.3% Upside
$43.20 Price Target
Short Interest: Bearish
13.47% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Selling Shares
$272,472 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($4.86) to ($4.97) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.97 out of 5 stars

Medical Sector

645th out of 948 stocks

Biological Products, Except Diagnostic Industry

108th out of 164 stocks

3.4

Analyst's Opinion

Consensus Rating
Tarsus Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $43.20, Tarsus Pharmaceuticals has a forecasted upside of 161.3% from its current price of $16.53.
Amount of Analyst Coverage
Tarsus Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
13.47% of the outstanding shares of Tarsus Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Tarsus Pharmaceuticals has a short interest ratio ("days to cover") of 9.2.
Change versus previous month
Short interest in Tarsus Pharmaceuticals has recently increased by 6.19%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Tarsus Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Tarsus Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for TARS.

3.3

News and Social Media Coverage

News Sentiment
Tarsus Pharmaceuticals has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Tarsus Pharmaceuticals this week, compared to 1 article on an average week.
Search Interest
4 people have searched for TARS on MarketBeat in the last 30 days.
MarketBeat Follows
Only 1 people have added Tarsus Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Tarsus Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $272,472.00 in company stock.
Percentage Held by Insiders
11.54% of the stock of Tarsus Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
70.02% of the stock of Tarsus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Tarsus Pharmaceuticals are expected to decrease in the coming year, from ($4.86) to ($4.97) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Tarsus Pharmaceuticals is -4.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Tarsus Pharmaceuticals is -4.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Tarsus Pharmaceuticals has a P/B Ratio of 2.56. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Tarsus Pharmaceuticals Stock (NASDAQ:TARS)

Tarsus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

TARS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

TARS Stock News Headlines

November 21, 2023 | msn.com

Goldman Sachs Initiates Coverage of Tarsus Pharmaceuticals (TARS) with Neutral Recommendation

November 21, 2023 | americanbankingnews.com

Tarsus Pharmaceuticals (NASDAQ:TARS) Coverage Initiated by Analysts at The Goldman Sachs Group

December 1, 2023 | Tomorrow Investor (Ad)

Why Microsoft Just Placed A Huge Bet On Nuclear

Even with aggressive expansion and acquisition of solar and wind farms, renewable energy isn’t anywhere close to providing the energy that Microsoft demands.

November 20, 2023 | markets.businessinsider.com

Hold Rating on Tarsus Pharmaceuticals: Analysis of Xdemvy’s Market Challenges and Future Potential

November 20, 2023 | msn.com

Goldman starts Tarsus at neutral, says Xdemvy launch faces headwinds

November 17, 2023 | markets.businessinsider.com

Oppenheimer Keeps Their Buy Rating on Tarsus Pharmaceuticals (TARS)

November 12, 2023 | finance.yahoo.com

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q3 2023 Earnings Call Transcript

November 12, 2023 | finance.yahoo.com

Analysts Are Betting On Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) With A Big Upgrade This Week

December 1, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.

November 11, 2023 | benzinga.com

Tarsus Pharmaceuticals Stock (NASDAQ:TARS), Analyst Ratings, Price Targets, Predictions

November 11, 2023 | markets.businessinsider.com

Promising Market Performance and Strong Sales Projection Uphold Buy Rating for Tarsus Pharmaceuticals

November 9, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: ANI Pharmaceuticals (ANIP), Rani Therapeutics Holdings (RANI) and Novavax (NVAX)

November 9, 2023 | msn.com

Tarsus files to sell $300M mixed securities shelf

November 9, 2023 | msn.com

Tarsus Pharmaceuticals GAAP EPS of -$1.28 beats by $0.11, revenue of $1.9M beats by $1.54M

November 9, 2023 | finance.yahoo.com

Tarsus Reports Third Quarter 2023 Financial Results and Recent Business Achievements

November 8, 2023 | morningstar.com

Tarsus Pharmaceuticals Inc Ordinary Shares TARS

November 8, 2023 | finance.yahoo.com

Recent uptick might appease Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) institutional owners after losing 11% over the past year

November 7, 2023 | finance.yahoo.com

IntegriChain Presents The Tina Patel Shining Light Award to Patrick Townsend of Vertex Pharmaceuticals

November 1, 2023 | finance.yahoo.com

Tarsus to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023

October 19, 2023 | msn.com

Tarsus Pharmaceuticals, Inc. - Barking Up The Wrong Tree

September 21, 2023 | markets.businessinsider.com

Analysts’ Top Healthcare Picks: Seelos Therapeutics (SEEL), Clene (CLNN)

September 12, 2023 | nasdaq.com

Guggenheim Maintains Tarsus Pharmaceuticals (TARS) Buy Recommendation

September 6, 2023 | finance.yahoo.com

Tarsus to Ring Nasdaq Stock Market Closing Bell in Celebration of the Launch of XDEMVY™, the First and Only FDA Approved Treatment for Demodex Blepharitis

September 4, 2023 | msn.com

Tarsus Pharmaceuticals: Worthy Of A Small Bet

August 30, 2023 | fool.com

Tarsus Pharmaceuticals (NASDAQ: TARS)

August 24, 2023 | finance.yahoo.com

Now Available – XDEMVY™ (lotilaner ophthalmic solution) 0.25%, the First and Only FDA Approved Treatment for Demodex Blepharitis

August 19, 2023 | finance.yahoo.com

Insider Spends US$160k Buying More Shares In Tarsus Pharmaceuticals

See More Headlines

Receive TARS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tarsus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/09/2021
Today: 11/30/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/11/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:TARS
CUSIP: N/A
CIK: 1819790
Web: www.tarsusrx.com
Phone: 949-409-9820
Fax: N/A
Employees: 87
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $43.20
High Stock Price Target: $54.00
Low Stock Price Target: $19.00
Potential Upside/Downside: +163.6%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.75
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.82)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-62,090,000.00
Net Margins: N/A
Pretax Margin: -748.73%
Return on Equity: -59.14%
Return on Assets: -48.01%

Debt

Debt-to-Equity Ratio: 0.14
Current Ratio: 11.15
Quick Ratio: 11.15

Sales & Book Value

Annual Sales: $25.82 million
Price / Sales: 21.01
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.45 per share
Price / Book: 2.54

Miscellaneous

Outstanding Shares: 33,100,000
Free Float: 29,285,000
Market Cap: $542.51 million
Optionable: Not Optionable
Beta: 0.79

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

Dr. Bobak R. Azamian M.D.
Co-Founder, President, CEO & Chairman
Dr. Bryan Wahl J.D. (Age 45)
M.D., General Counsel & Corporate Secretary
Comp: $619.09k
Dr. Elizabeth Yeu Lin M.D. (Age 45)
Chief Medical Advisor & Director
Comp: $286k
Dr. Jose Trevejo M.D. (Age 51)
Ph.D., Chief Medical Officer
Comp: $769.39k
Mr. Jeffrey S. Farrow (Age 61)
CFO & Chief Strategy Officer
Dr. Seshadri Neervannan Ph.D. (Age 55)
Chief Operating Officer
Comp: $486.67k
Mr. David Nakasone
Head of Investor Relations
Ms. Adrienne Kemp
Senior Director of Corporate Communications
Mr. Matthew Rossen M.B.A. (Age 46)
Vice President of Marketing
Mr. Scott Youmans
Vice President of Sales

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

TARS Stock Analysis - Frequently Asked Questions

Should I buy or sell Tarsus Pharmaceuticals stock right now?: 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Tarsus Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" TARS shares.
View TARS analyst ratings or view top-rated stocks.
What is Tarsus Pharmaceuticals' stock price target for 2024?: 4 brokerages have issued 1 year target prices for Tarsus Pharmaceuticals' stock. Their TARS share price targets range from $19.00 to $54.00. On average, they expect the company's share price to reach $43.20 in the next twelve months. This suggests a possible upside of 161.3% from the stock's current price.
View analysts price targets for TARS or view top-rated stocks among Wall Street analysts.
How have TARS shares performed in 2023?: Tarsus Pharmaceuticals' stock was trading at $14.66 at the beginning of the year. Since then, TARS shares have increased by 12.8% and is now trading at $16.53.
View the best growth stocks for 2023 here.
When is Tarsus Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, March 11th 2024.
View our TARS earnings forecast.
How were Tarsus Pharmaceuticals' earnings last quarter?: Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) posted its quarterly earnings results on Tuesday, November, 9th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by $0.34. The firm earned $1.24 million during the quarter, compared to analysts' expectations of $1 million.

What ETF holds Tarsus Pharmaceuticals' stock ?: Invesco Raymond James SB-1 Equity ETF holds 39,637 shares of TARS stock, representing 0.71% of its portfolio.
When did Tarsus Pharmaceuticals IPO?: (TARS) raised $80 million in an initial public offering (IPO) on Friday, October 16th 2020. The company issued 5,000,000 shares at $15.00-$17.00 per share. BofA Securities, Jefferies and Raymond James served as the underwriters for the IPO and LifeSci Capital and Ladenburg Thalmann were co-managers.
Who are Tarsus Pharmaceuticals' major shareholders?: Tarsus Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include RTW Investments LP (8.70%), Cowen AND Company LLC (5.51%), Deerfield Management Company L.P. Series C (2.28%), Artisan Partners Limited Partnership (1.22%), Allspring Global Investments Holdings LLC (0.75%) and Schonfeld Strategic Advisors LLC (0.74%). Insiders that own company stock include Aziz Mottiwala, Bobak R Azamian, Bobak R Azamian, Bryan Wahl, Dianne C Whitfield, Elizabeth Yeu Lin, Jose M Trevejo, Leonard M Greenstein, Mark J Holdbrook, Michael Ackermann, Rtw Investments, Lp, Seshadri Neervannan and Vivo Capital Ix, Llc.
View institutional ownership trends.
How do I buy shares of Tarsus Pharmaceuticals?: Shares of TARS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:TARS) was last updated on 12/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial